SCHEMBL7643175

SCHEMBL7643175

O=C(O)CCC(c1ccc2ccccc2c1)N(Cc1ccccc1)[PH](=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 4/20 0.41
CYP1A2 P05177 2/20 0.40
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
MC4R P32245 1/20 0.39
MC5R P33032 1/20 0.39
MC1R Q01726 1/20 0.39
CYSLTR2 Q9NS75 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
ACHE P22303 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
CPA3 P15088 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7645014 0.79 CHRNB2 (0.37) CPA3
SCHEMBL3380508 0.74 CPA3 (0.46) CYP1A2HDAC1HDAC8CYP3A4CYP2D6
SCHEMBL7645583 0.73 PPARG (0.42) UTS2RCYP1A2HDAC1HDAC8CYSLTR2
SCHEMBL7643171 0.72 CYP1A2 (0.44) UTS2RCYP1A2HDAC1MC4RMC5R
SCHEMBL6503796 0.70 HDAC1 (0.65) CYP1A2HDAC1HDAC8CYP3A4CYP2D6
SCHEMBL28936618 0.69 HDAC1 (0.49) CYP1A2HDAC1HDAC8CYP3A4CYP2D6
SCHEMBL7450034 0.69 HDAC1 (0.49) UTS2RCYP1A2HDAC1HDAC8MC4R
SCHEMBL7677415 0.69 HDAC1 (0.49) CYP1A2HDAC1HDAC8CYSLTR2CYSLTR1
SCHEMBL7645575 0.69 CYP1A2 (0.55) CYP1A2HDAC1HDAC8MC4RMC5R
SCHEMBL4155106 0.68 CPA3 (0.47) CYP1A2HDAC1HDAC8CYP2D6SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151503-A1 Methods of cancer treatment using naaladase inhibitors SLUSHER BARBARA S (US) 2002-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151503-A1 Methods of cancer treatment using naaladase inhibitors NAALAD2, DNPEP, ACP3 UTS2R 1436/4885CYP1A2 4583/4885HDAC1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.